145 related articles for article (PubMed ID: 28454385)
1. Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer.
Liu Y; He J; Xu J; Li J; Jiao Y; Bei D; Hu Y; Chen H; Xiao Q; Ding K
Oncol Lett; 2017 Apr; 13(4):2230-2236. PubMed ID: 28454385
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation is a prognostic factor for stage II poorly differentiated colorectal cancer.
Liu Y; Xu J; Jiao Y; Hu Y; Yi C; Li Q; Tong Z; Wang X; Hu L; Xiao Q; Li J; Ding K
Biomed Res Int; 2014; 2014():789575. PubMed ID: 25093184
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine-like differentiation in patients with pancreatic carcinoma.
Tezel E; Nagasaka T; Nomoto S; Sugimoto H; Nakao A
Cancer; 2000 Dec; 89(11):2230-6. PubMed ID: 11147593
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma.
Zhang T; Su D; Mao Z; Guo X; Wang L; Bai L
Int J Clin Exp Med; 2015; 8(5):7837-42. PubMed ID: 26221337
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and survival analysis of gastric cancer patients with neuroendocrine differentiation after radical resection].
Yu S; Lyu MZ; Luo RK; Liu FL; Liu TS
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):426-432. PubMed ID: 34000772
[No Abstract] [Full Text] [Related]
6. Neuroendocrine differentiation: a risk fellow in colorectal cancer.
Chen Y; Liang Y; Cao L; Dong X; Sun D
World J Surg Oncol; 2023 Mar; 21(1):89. PubMed ID: 36899368
[TBL] [Abstract][Full Text] [Related]
7. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients.
Sawaki M; Yokoi K; Nagasaka T; Watanabe R; Kagawa C; Takada H; Sato S; Yamada T; Kikumori T; Imai T; Nakao A
Surg Today; 2010 Sep; 40(9):831-5. PubMed ID: 20740345
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of neuroendocrine differentiation in colorectal cancer: a population-based, propensity score matching study.
Guo J; Zheng P; Wang R; Tan X; Yang W; Xiao S; Chen Z
Int J Colorectal Dis; 2020 Dec; 35(12):2185-2195. PubMed ID: 32720185
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of neuroendocrine components in gastric carcinomas.
Park JY; Ryu MH; Park YS; Park HJ; Ryoo BY; Kim MG; Yook JH; Kim BS; Kang YK
Eur J Cancer; 2014 Nov; 50(16):2802-9. PubMed ID: 25201164
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
[TBL] [Abstract][Full Text] [Related]
12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
15. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Features and Postoperative Survival Analysis of Gastric Carcinoma with Neuroendocrine Differentiation.
Liu J; Pan X; Sun Y; Dong T; Hu X; Zhong H; Lu J
J Oncol; 2022; 2022():4440098. PubMed ID: 36035314
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
19. Survival comparison of pulmonary neuroendocrine carcinoma, adenocarcinoma with neuroendocrine differentiation, and adenocarcinoma.
Tai Q; Bao Y; Song N; Hu X; Duan L
J Thorac Dis; 2024 Jan; 16(1):604-614. PubMed ID: 38410570
[TBL] [Abstract][Full Text] [Related]
20. Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer.
Shang A; Wang S; Yang Y; Li L; Zhao Z; Li D; Guo Y; Wang M
World J Surg Oncol; 2021 Mar; 19(1):84. PubMed ID: 33752702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
